Named Lecture:
225. John F. Enders Lecture
Saturday, October 20, 2012: 3:45 PM-4:30 PM
Room: Ballroom 20 ABCD

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss the roles of illicit drug use in transmission of hepatitis C virus (HCV) and pharmaceutical drugs in curing infection
  • describe how the diversity of the virus and host DNA affect HCV infection and its treatment
  • contrast HCV infection in persons with and without HIV to identify the opportunities for eradication of HCV infection

Target Audience: Vaccinologists, Scientists, Researchers, Public Health Practitioners, Pharmacists, Nurses, Microbiologists, Lab Personnel, Investigators, Infectious Diseases Physicians, Infectious Diseases Pediatricians, Infection Preventionists, Hospital Epidemiologists, Hospital Administrators, HIV Specialists, HIV Clinicians, Health Care Workers, Fellows-in-Training, Fellows, Epidemiologists, Clinicians, Academicians

Tracks: Epidemiology and Infection Control, Global ID, Investigative ID, HIV-STD-TB, Pediatric ID, Adult ID

Moderator:  Liise-anne Pirofski, MD, FIDSA, Montefiore Medical Center and the Albert Einstein College of Medicine

Presentations:

3:45 PM
Hepatitis C: Challenge and Opportunity
David Thomas, MD, MPH, FIDSA

CME Credits: Maximum of 0.75 hour of AMA PRA Category 1 CreditTM

Disclosures:

L. A. Pirofski, None

D. Thomas, Merck : Grant Investigator and Scientific Advisor, Consulting fee and Research support
Gilead: Grant Investigator and Scientific Advisor, Research support
Jansen: Scientific Advisor, Consulting fee

See more of: Named Lecture

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.